Form 4: Vaxcyte Executive Jim Wassil Reports Stock Option Exercises

Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., reports exercising stock options at prices of $5.35 and $20.93 on October 28, 2024.

Summary

• On October 28, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc. (PCVX), executed transactions involving Vaxcyte's common stock.
• Wassil exercised stock options to acquire 1,585 shares at $5.35 and 3,464 shares at $20.93.
• Following these transactions, Wassil directly owns 205,695 shares of Vaxcyte common stock.
• The exercised stock options were fully vested or vesting monthly, subject to continuous service with Vaxcyte.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option exercises. It doesn't inherently indicate positive or negative performance for the company.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies within the biotechnology sector.

Comparison to Industry Standards

• Executive stock option exercises are a common form of compensation in the biotech industry.
• Companies like Moderna and BioNTech also grant stock options to their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• The stock option exercises may have a minor dilutive effect on existing shareholders.
• The exercises incentivize the COO to continue driving company performance.

Key Dates